Legend Biotech Announces CEO Resignation and Interim Leadership
Legend Biotech Corporation (NASDAQ: LEG N) disclosed that Chief Executive Officer Ying Huang has stepped down from his position and from the Board of Directors. The announcement triggered a 5.7% decline in the company’s shares during pre‑market trading on Monday.
Interim CEO Appointment and Transition Plan
The Board appointed Alan Bash, who currently serves as President of the CARVYKTI Business Unit, as Interim Chief Executive Officer effective July 24. Ying Huang will remain with the company as an advisor through August to facilitate a smooth transition. Concurrently, the Board, chaired by Frank Zhang, has launched a search process to identify a permanent successor.
Company Background and Strategic Focus
Ying Huang led Legend Biotech for seven years, during which the firm evolved from a pioneering cell‑therapy company into a commercial‑stage organization. Legend Biotech develops and markets CARVYKTI, a CAR‑T cell therapy targeting relapsed or refractory multiple myeloma, in collaboration with Johnson & Johnson. The Board expressed confidence that Bash’s commercial and operational experience, particularly within the CARVYKTI business, will ensure continuity of execution across commercial, clinical, and operational priorities.
Analyst Reaction
RBC Capital analyst Leonid Timashev revised his price target for Legend Biotech downward to $59.00 from $63.00, while maintaining an Outperform rating on the stock.
Company Profile
Legend Biotech employs over 3,000 people and is headquartered in Bridgewater, New Jersey.